1. Home
  2. IGR vs ANNX Comparison

IGR vs ANNX Comparison

Compare IGR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$4.54

Market Cap

645.2M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.64

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGR
ANNX
Founded
2004
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.2M
730.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
IGR
ANNX
Price
$4.54
$5.64
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
709.7K
2.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
13.93%
N/A
EPS Growth
N/A
42.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.20
$1.29
52 Week High
$5.37
$7.18

Technical Indicators

Market Signals
Indicator
IGR
ANNX
Relative Strength Index (RSI) 29.41 51.82
Support Level $4.49 $4.77
Resistance Level $5.04 $7.18
Average True Range (ATR) 0.08 0.35
MACD -0.05 0.06
Stochastic Oscillator 0.99 46.85

Price Performance

Historical Comparison
IGR
ANNX

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: